Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 11 | 2018 | 30 | 2.060 |
Why?
|
| Liver Failure, Acute | 3 | 2018 | 4 | 0.700 |
Why?
|
| Galactosyltransferases | 2 | 2012 | 2 | 0.690 |
Why?
|
| Liver | 4 | 2019 | 57 | 0.630 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2010 | 9 | 0.540 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 47 | 0.520 |
Why?
|
| Transplantation, Heterologous | 2 | 2016 | 10 | 0.490 |
Why?
|
| Neuroendocrine Tumors | 3 | 2019 | 28 | 0.420 |
Why?
|
| Hypertension, Malignant | 1 | 2012 | 1 | 0.360 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 51 | 0.350 |
Why?
|
| Humans | 23 | 2022 | 12240 | 0.340 |
Why?
|
| Hepatectomy | 3 | 2017 | 29 | 0.340 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 24 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 47 | 0.310 |
Why?
|
| Endothelial Cells | 1 | 2010 | 37 | 0.310 |
Why?
|
| Retrospective Studies | 9 | 2022 | 1467 | 0.280 |
Why?
|
| Living Donors | 2 | 2004 | 6 | 0.260 |
Why?
|
| Liver Regeneration | 2 | 2017 | 12 | 0.260 |
Why?
|
| Male | 14 | 2020 | 6815 | 0.250 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 168 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 61 | 0.250 |
Why?
|
| Survival Rate | 5 | 2020 | 152 | 0.240 |
Why?
|
| Bile Duct Neoplasms | 1 | 2005 | 1 | 0.220 |
Why?
|
| Middle Aged | 11 | 2020 | 4043 | 0.220 |
Why?
|
| Time Factors | 4 | 2022 | 695 | 0.220 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2004 | 8 | 0.220 |
Why?
|
| Female | 11 | 2020 | 6974 | 0.210 |
Why?
|
| Hepatitis B, Chronic | 1 | 2003 | 2 | 0.200 |
Why?
|
| Swine | 3 | 2016 | 43 | 0.200 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 21 | 0.200 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2022 | 8 | 0.180 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.180 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 8 | 0.180 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 7 | 0.180 |
Why?
|
| Gastroparesis | 1 | 2022 | 3 | 0.180 |
Why?
|
| Hospitals, University | 1 | 2001 | 12 | 0.180 |
Why?
|
| Specialization | 1 | 2001 | 5 | 0.180 |
Why?
|
| Pancreas Transplantation | 1 | 2021 | 13 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 9 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2021 | 20 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 31 | 0.170 |
Why?
|
| Animals | 4 | 2017 | 2092 | 0.160 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2020 | 4 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2020 | 5 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 16 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2019 | 2 | 0.150 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2019 | 2 | 0.150 |
Why?
|
| Jejunostomy | 1 | 2019 | 4 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2020 | 75 | 0.150 |
Why?
|
| Pancreatectomy | 1 | 2019 | 6 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2022 | 385 | 0.150 |
Why?
|
| Pancreas | 1 | 2019 | 16 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 11 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 68 | 0.140 |
Why?
|
| Portal Vein | 2 | 2017 | 19 | 0.140 |
Why?
|
| Heat Stroke | 1 | 2018 | 1 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 18 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 14 | 0.140 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 10 | 0.140 |
Why?
|
| Liver Failure | 1 | 2018 | 6 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 22 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 32 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 24 | 0.140 |
Why?
|
| Ligation | 1 | 2017 | 19 | 0.130 |
Why?
|
| Adult | 5 | 2020 | 3557 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2022 | 1478 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2017 | 15 | 0.120 |
Why?
|
| Graft Survival | 2 | 2016 | 44 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 85 | 0.120 |
Why?
|
| Papio | 2 | 2016 | 6 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2014 | 14 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 10 | 0.100 |
Why?
|
| Risk Factors | 3 | 2022 | 1049 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 726 | 0.090 |
Why?
|
| Papio hamadryas | 1 | 2012 | 1 | 0.090 |
Why?
|
| Swine, Miniature | 1 | 2012 | 4 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 6 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 12 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 53 | 0.090 |
Why?
|
| Hepatic Encephalopathy | 1 | 2012 | 1 | 0.090 |
Why?
|
| Intracranial Hypertension | 1 | 2012 | 3 | 0.090 |
Why?
|
| Intracranial Pressure | 1 | 2012 | 5 | 0.090 |
Why?
|
| Patient Selection | 2 | 2019 | 111 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 15 | 0.090 |
Why?
|
| United States | 3 | 2020 | 989 | 0.090 |
Why?
|
| Aged | 4 | 2020 | 4000 | 0.080 |
Why?
|
| End Stage Liver Disease | 1 | 2010 | 6 | 0.080 |
Why?
|
| Complement C3a | 1 | 2010 | 1 | 0.080 |
Why?
|
| Complement Activation | 1 | 2010 | 4 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 8 | 0.080 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 8 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 38 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 69 | 0.080 |
Why?
|
| Reoperation | 1 | 2012 | 366 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 141 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 363 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 61 | 0.070 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 1 | 0.070 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 4 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 10 | 0.070 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2006 | 2 | 0.060 |
Why?
|
| Graft Rejection | 2 | 2020 | 30 | 0.060 |
Why?
|
| Hepatoblastoma | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cholangiocarcinoma | 1 | 2005 | 1 | 0.060 |
Why?
|
| Waiting Lists | 1 | 2005 | 4 | 0.060 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 2 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2005 | 23 | 0.050 |
Why?
|
| Contrast Media | 1 | 2004 | 32 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2022 | 8 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 11 | 0.050 |
Why?
|
| Pancreatic Fistula | 1 | 2022 | 1 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 464 | 0.040 |
Why?
|
| Steroids | 1 | 2022 | 12 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2022 | 37 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2001 | 22 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 42 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 78 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 12 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 10 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 51 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 14 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 28 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 161 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 8 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 13 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 38 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 116 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 42 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 99 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 118 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 179 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 156 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 338 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 29 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 863 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 989 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2017 | 12 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 453 | 0.030 |
Why?
|
| Hypoxia | 1 | 2017 | 14 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 166 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 827 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 2152 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 1 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2008 | 2 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2008 | 2 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 6 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 18 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 50 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 97 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 143 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 93 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 157 | 0.020 |
Why?
|
| Kidney | 1 | 2008 | 87 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2006 | 4 | 0.010 |
Why?
|
| Biliary Tract | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2004 | 2 | 0.010 |
Why?
|
| Hepatic Veins | 1 | 2004 | 3 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 13 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 42 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 81 | 0.010 |
Why?
|